Here's why the Imugene (ASX:IMU) share price is rising 9% today

The Imugene Limited (ASX: IMU) share price is rising today after announcing the successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy.

The Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company received a successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy.

PD1-Vaxx is a B-cell immunotherapy designed to treat tumours by producing polyclonal antibodies that block PD-1 signalling, causing an anti-cancer effect.

During mid-afternoon trade, the Imugene shares are up 9.5% to 12 cents.

Female scientist in lab examines coronavirus vaccine

Image source: Getty Images

First checkpoint passed

The Imugene share price is rising deeper into positive territory following the release.

According to Imugene, the CRC cleared the pathway for phase I clinical trials to be proceed with a higher dose of PD1-Vaxx.

Following patient data review, CRC unanimously decided that the immunotherapy candidate is safe with no dose-limiting toxicities or adverse reactions.

CRC advised that Imugene can now administer a stronger 50 micrograms 'mid-dose' level to patients in the first-stage clinical trial.

Originally, the company provided a dose of just 10 micrograms of PD1-Vaxx to participants as monotherapy during the initial study.

Imugene noted that clinicians from Australia and the United States will also look into the underlying benefits of PD1-Vaxx. This includes understanding if patients who are treated with the PD1-Vaxx as a monotherapy will prolong survival, delay tumour progression, or reduce tumour discomfort in patients with lung cancer.

Words from management

Imugene Managing Director and CEO, Ms. Leslie Chong, hailed the positive results, saying:

We are pleased with the results that we have seen so far with no observed toxicity. Everyone supporting the study who are involved in developing this important new cancer therapy are very encouraged by the progress to date. We look forward to continuing this study and reporting to the market of its progress.

About the Imugene share price

The Imugene share price has performed relatively well over the past 12 months, up over 228%.

Its shares reached a 52-week low of 1.6 cents before surging high in late 2020, recording an all-time high of 14 cents.

Based on the current share price, the company's market capitalisation now presides at $545 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Happy wife holding her hands on her husband's shoulders while both look at a laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man stands in front of a chart with an arrow going down and slaps his forehead in frustration.
ASX Share Market News

ASX 200 mining shares smashed in major market sell-off

The ASX 200 fell 5.39% amid a mining sell-off, with BHP shares tumbling almost 13% last week.

Read more »

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »